Evaluation of Palliative Care for Patients With ALS and Their Caregivers
NCT04257760 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66
Last updated 2024-04-03
Summary
Rationale: Amyotrophic lateral sclerosis (ALS) is a degenerative illness which currently has no medical cure. It is routinely accompanied by a significant symptom burden including high levels of distress in patients and their caregivers. As a result, an early palliative care approach is recommended in the ALS population. Palliative care has been shown to have positive effects on the quality of life in patients and caregivers in other life limiting illness such as cancer and multiple sclerosis. Unfortunately, our understanding of the palliative care needs in ALS is limited and the efficacy of palliative care involvement is poorly understood. Furthermore, ALS patients are largely underserved by palliative care in Ontario, with \<50% of ALS patients receiving palliative care even in the last year of life. Hypothesis: The investigators hypothesize that ALS patients will be agreeable to palliative care consultations and that this will improve the quality of life of patients and their caregivers. Specific Aims: This project seeks to initiate routine palliative care consultation in an interdisciplinary ALS clinic to: 1) improve patient and caregiver quality of life, 2) further understand the palliative care needs of the ALS population and 3) identify which patients and caregivers are most likely to benefit from palliative care consultation, thus guiding clinicians on when to refer in the future. Significance: This study is the first investigate the feasibility and efficacy of palliative care consultation in the ALS population, and its effects on quality of life. It has the potential to provide increased support to patients as well as caregivers. Finally, this study will aid in our understanding of the optimal time to involve palliative care in the ALS population and will act as a foundation on which larger, controlled studies can be built.
Conditions
Interventions
- BEHAVIORAL
-
Palliative Care consultation outside standard of care
The ALS patients and their caregivers will receive a consultation with a palliative care physician. This will take approximately one hour and occur in their location of choice (ie. often the patient's home). Subsequent palliative care consultations will occur at the discretion of the ALS patient and the palliative care physician.
Sponsors & Collaborators
-
ALS Society of Canada
collaborator OTHER_GOV -
Ottawa Hospital Research Institute
lead OTHER
Principal Investigators
-
Jocelyn C Zwicker, MD · The Ottawa Hospital
-
Christine Watt, MD · The Ottawa Hospital
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-10-08
- Primary Completion
- 2022-10-30
- Completion
- 2022-10-30
Countries
- Canada
Study Locations
More Related Trials
-
Study of the Effects Strengthening Exercises in Individuals With ALS
NCT00204464 ·Status: COMPLETED ·Phase: PHASE2
-
Open Label Study: Treatment of ALS Fatigue With PolyMVA
NCT04557410 ·Status: COMPLETED ·Phase: PHASE1
-
Respiratory Complications in ALS
NCT04430686 ·Status: COMPLETED
-
Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation
NCT00116558 ·Status: COMPLETED ·Phase: NA
-
Peripheral Neurofilament Levels and Amyotrophic Lateral Sclerosis
NCT04455542 ·Status: COMPLETED
-
Mitochondrial Functions and Oxidative Stress in ALS Patients
NCT00331812 ·Status: UNKNOWN
-
Nerve Growth Factor Encapsulated With 2-methacryloyloxyethyl Phosphorylcholine Nanocapsules in the Treatment of Amyotrophic Lateral Sclerosis
NCT06391645 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Determinants of Disease Severity in Amyotrophic Lateral Sclerosis
NCT00004457 ·Status: UNKNOWN
-
Ultra-high-caloric, Fatty Diet in ALS
NCT06280079 ·Status: RECRUITING ·Phase: NA
-
Determining the Safety of L-serine in ALS
NCT01835782 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis
NCT01492686 ·Status: COMPLETED ·Phase: PHASE3
-
Registration Study of Amyotrophic Lateral Sclerosis (ALS) in Mainland China
NCT04328675 ·Status: UNKNOWN
-
Methodology Study of Novel Outcome Measures to Assess Progression of ALS
NCT02611674 ·Status: COMPLETED
-
Amyotrophic Lateral Sclerosis and the Innate Immune System
NCT02869048 ·Status: RECRUITING
-
Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis
NCT02969759 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Autologous Multipotent Mesenchymal Stromal Cells in the Treatment of Amyotrophic Lateral Sclerosis
NCT03828123 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Noninvasive Examination of the Work of Breathing in Patients With Amyotrophic Lateral Sclerosis (ALS).
NCT00718003 ·Status: TERMINATED
-
Amyotrophic Lateral Sclerosis (ALS) Families Project
NCT03865420 ·Status: RECRUITING
-
Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS)
NCT04454892 ·Status: RECRUITING
-
A Patient Centric Motor Neuron Disease Activities of Daily Living Scale
NCT02852278 ·Status: COMPLETED
-
A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALS
NCT05279755 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Neurofilament Light Chain in Amyotrophic Lateral Sclerosis
NCT06201650 ·Status: RECRUITING
-
LONgitudinal and Integrated Evaluation of Biomarkers in reLation to phenotYpe in ALS
NCT07312240 ·Status: RECRUITING ·Phase: NA
-
Clinical Trial - Analyzing Participation Experiences Of Amyotrophic Lateral Sclerosis Patients
NCT05423678 ·Status: NOT_YET_RECRUITING
-
A Programme for Amyotrophic Lateral Sclerosis Care in Europe
NCT03081338 ·Status: UNKNOWN